Lanreotide
Also referenced as: Somatuline Depot
A long-acting somatostatin analogue used for selected endocrine and neuroendocrine tumor conditions.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
Somatuline Depot is FDA-approved for specified acromegaly, advanced GEP-NET and carcinoid-syndrome indications; consult the product-specific label.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A long-acting somatostatin analogue used for selected endocrine and neuroendocrine tumor conditions.
Somatuline Depot is FDA-approved for specified acromegaly, advanced GEP-NET and carcinoid-syndrome indications; consult the product-specific label.
Progression-free survival is not a cure or necessarily an overall-survival benefit. Endocrine and tumor indications have distinct criteria.
Why It's Being Studied
- Acromegaly
- Gastroenteropancreatic neuroendocrine tumors
- Carcinoid symptoms
Mechanism of Action
Somatostatin-receptor activation suppresses hormone secretion and can slow growth signalling in receptor-positive tumors.
Somatostatin-receptor activation suppresses hormone secretion and can slow growth signalling in receptor-positive tumors. Progression-free survival is not a cure or necessarily an overall-survival benefit. Endocrine and tumor indications have distinct criteria.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Acromegaly
- Gastroenteropancreatic neuroendocrine tumors
- Carcinoid symptoms
- Subcutaneous approved depot medicine
Evidence Summary
Randomized neuroendocrine tumor evidence supports improved progression-free survival; other studies support biochemical and symptom control.
Higher tiers carry more weight. Filled tiers have evidence for Lanreotide; tap to read it.
- Randomized neuroendocrine tumor evidence supports improved progression-free survival; other studies support biochemical and symptom control.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Randomized neuroendocrine tumor evidence supports improved progression-free survival; other studies support biochemical and symptom control.
Reported Adverse Events in Research
- Gallstones, glucose disturbances, bradycardia and fat malabsorption or pancreatic exocrine insufficiency are important risks.
Limitations of Current Evidence
- Progression-free survival is not a cure or necessarily an overall-survival benefit. Endocrine and tumor indications have distinct criteria.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Lanreotide | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved depot medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Lanreotide — prescribing label